Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Bienkowska, Jadwiga ^a   Norm, Allaire ^a   Thai, Alice ^a   Goyal, Jaya ^a   Plavina, Tatiana ^a   Nirula, Ajay ^a   Weaver, Megan ^a   Newman, Charlotte ^a   Petri, Michelle ^b   Beckman, Evan ^a   Browning, Jeffrey L ^a,c  

^a BIOGEN   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAMINERCEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HERPESVIRUS ENTRY MEDIATOR LIGAND; INTERFERON; LYMPHOTOXIN; LYMPHOTOXIN BETA RECEPTOR; PLACEBO; RNA; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; HYBRID PROTEIN; LYMPHOTOXIN ALPHA BETA; MESSENGER RNA;

ARTICLE; CYTOKINE RESPONSE; DRUG WITHDRAWAL; GENE EXPRESSION; HUMAN; INTERFERON PRODUCTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MONOCYTE; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ARTHRITIS, RHEUMATOID; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERFERONS; LYMPHOTOXIN ALPHA1, BETA2 HETEROTRIMER; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER;

EID: 84913559696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112545     Document Type: Article

References (75)

1. Ronnblom L, Eloranta ML (2013) The interferon signature in autoimmune diseases. Current opinion in rheumatology 25: 248-253
2. Elkon KB, Wiedeman A (2012) Type I IFN system in the development and manifestations of SLE. Current opinion in rheumatology 24: 499-505
3. Higgs BW, Liu Z, White B, Zhu W, White WI, et al. (2011) Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Annals of the rheumatic diseases 70: 2029-2036
4. Crow YJ (2011) Type I interferonopathies: A novel set of inborn errors of immunity. Annals of the New York Academy of Sciences 1238: 91-98
5. Kirou KA, Gkrouzman E (2013) Anti-interferon alpha treatment in SLE. Clinical immunology 148: 303-312
6. Browning JL (2008) Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunological reviews 223: 202-220
7. Ware CF (2008) Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunological reviews 223: 186-201
8. Remouchamps C, Boutaffala L, Ganeff C, Dejardin E (2011) Biology and signal transduction pathways of the Lymphotoxin-alphabeta/LTbetaR system. Cytokine & growth factor reviews 22: 301-310
9. Lu TT, Browning JL (2014) Role of the Lymphotoxin/LIGHT System in the Development and Maintenance of Reticular Networks and Vasculature in Lymphoid Tissues. Frontiers in immunology 5: 47
10. Gray EE, Cyster JG (2012) Lymph node macrophages. Journal of innate immunity 4: 424-436
11. Summers deLuca L, Gommerman JL (2012) Fine-tuning of dendritic cell biology by the TNF superfamily. Nature reviews Immunology 12: 339-351
12. De Trez C (2012) Lymphotoxin-beta receptor expression and its related signaling pathways govern dendritic cell homeostasis and function. Immunobiology 217: 1250-1258
13. Upadhyay V, Fu YX (2013) Lymphotoxin signalling in immune homeostasis and the control of microorganisms. Nature reviews Immunology 13: 270-279
14. Satpathy AT, Briseno CG, Lee JS, Ng D, Manieri NA, et al. (2013) Notch2- dependent classical dendritic cells orchestrate intestinal immunity to attachingand- effacing bacterial pathogens. Nature immunology 14: 937-948
15. Wege AK, Huber B, Wimmer N, Mannel DN, Hehlgans T (2013) LTbetaR expression on hematopoietic cells regulates acute inflammation and influences maturation of myeloid subpopulations. Innate immunity ePub
16. Steinberg MW, Cheung TC, Ware CF (2011) The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunological reviews 244: 169-187
17. Allaire NE, Bushnell SE, Bienkowska J, Brock G, Carulli J (2013) Optimization of a high-throughput whole blood expression profiling methodology and its application to assess the pharmacodynamics of interferon (IFN) beta-1a or polyethylene glycol-conjugated IFN beta-1a in healthy clinical trial subjects. BMC research notes 6: 8
18. Rose T, Grutzkau A, Hirseland H, Huscher D, Dahnrich C, et al. (2013) IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Annals of the rheumatic diseases 72: 1639-1645
19. Hall JC, Casciola-Rosen L, Berger AE, Kapsogeorgou EK, Cheadle C, et al. (2012) Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proceedings of the National Academy of Sciences of the United States of America 109: 17609-17614
20. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, et al. (2010) Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PloS one 5: e9753
21. Hua J, Kirou K, Lee C, Crow MK (2006) Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis and rheumatism 54: 1906-1916
22. Mavragani CP, La DT, Stohl W, Crow MK (2010) Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: A post hoc analysis of a predominantly Hispanic cohort. Arthritis and rheumatism 62: 392-401
23. Kirou KA, Lee C, George S, Louca K, Peterson MG, et al. (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis and rheumatism 52: 1491-1503
24. Browning JL, Allaire N, Ngam-Ek A, Notidis E, Hunt J, et al. (2005) Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity 23: 539-550
25. Cyster JG, Schwab SR (2012) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annual review of immunology 30: 69-94
26. Silva-Santos B, Pennington DJ, Hayday AC (2005) Lymphotoxin-mediated regulation of gammadelta cell differentiation by alphabeta T cell progenitors. Science 307: 925-928
27. Elewaut D, Ware CF (2007) The unconventional role of LT alpha beta in T cell differentiation. Trends in immunology 28: 169-175
28. Vallabhapurapu S, Powolny-Budnicka I, Riemann M, Schmid RM, Paxian S, et al. (2008) Rel/NF-kappaB family member RelA regulates NK1.1- to NK1.1+ transition as well as IL-15-induced expansion of NKT cells. European journal of immunology 38: 3508-3519
29. Powolny-Budnicka I, Riemann M, Tanzer S, Schmid RM, Hehlgans T, et al. (2011) RelA and RelB transcription factors in distinct thymocyte populations control lymphotoxin-dependent interleukin-17 production in gammadelta T cells. Immunity 34: 364-374
30. Van Den Broeck T, Van Ammel E, Delforche M, Taveirne S, Kerre T, et al. (2013) Differential Ly49e expression pathways in resting versus TCR-activated intraepithelial gammadelta T cells. Journal of immunology 190: 1982-1990
31. Verma S, Wang Q, Chodaczek G, Benedict CA (2013) Lymphoid-tissue stromal cells coordinate innate defense to cytomegalovirus. Journal of virology 87: 6201-6210
32. Knight JS, Kaplan MJ (2012) Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. Current opinion in rheumatology 24: 441-450
33. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, et al. (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Science translational medicine 5: 178ra140
34. Lepelletier Y, Zollinger R, Ghirelli C, Raynaud F, Hadj-Slimane R, et al. (2010) Toll-like receptor control of glucocorticoid-induced apoptosis in human plasmacytoid predendritic cells (pDCs). Blood 116: 3389-3397
35. Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, et al. (2010) TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465: 937-941
36. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, et al. (2009) Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis and rheumatism 60: 1785-1796
37. McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, et al. (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis and rheumatism 64: 3666-3676
38. Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, et al. (2013) Sifalimumab, a Human Anti-Interferon-alpha Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose- Escalation Study. Arthritis and rheumatism 65: 1011-1021
39. Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, et al. (2013) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Annals of the rheumatic diseases 78: 256-262
40. Huang YL, Chung HT, Chang CJ, Yeh KW, Chen LC, et al. (2009) Lymphopenia is a risk factor in the progression of carotid intima-media thickness in juvenile-onset systemic lupus erythematosus. Arthritis and rheumatism 60: 3766-3775
41. Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, et al. (2010) Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology 49: 156-166
42. Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, et al. (2010) Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis and rheumatism 62: 3607-3614
43. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, et al. (2012) The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis research & therapy 14: R95
44. Reynier F, Petit F, Paye M, Turrel-Davin F, Imbert PE, et al. (2011) Importance of correlation between gene expression levels: Application to the type I interferon signature in rheumatoid arthritis. PloS one 6: e24828
45. van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, et al. (2010) Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis research & therapy 12: R11
46. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J (2005) Crossregulation of TNF and IFN-alpha in autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America 102: 3372-3377
47. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, et al. (2007) Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis and rheumatism 56: 3995-4004
48. Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, et al. (2010) Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis and rheumatism 62: 589-598
49. de Bruin AM, Libregts SF, Valkhof M, Boon L, Touw IP, et al. (2012) IFNgamma induces monopoiesis and inhibits neutrophil development during inflammation. Blood 119: 1543-1554
50. Cain DW, Snowden PB, Sempowski GD, Kelsoe G (2011) Inflammation triggers emergency granulopoiesis through a density-dependent feedback mechanism. PloS one 6: e19957
51. Hartrich L, Weinstock-Guttman B, Hall D, Badgett D, Baier M, et al. (2003) Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients. Journal of neuroimmunology 139: 84-92
52. Gao Y, Majchrzak-Kita B, Fish EN, Gommerman JL (2009) Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by interferon-beta. Blood 114: 2623-2631
53. Gommerman J.L B, C.F W (2014) The Lymphotoxin Network: Orchestrating a Type I Interferon response to optimize adaptive immunity. Cytokine & growth factor reviews in press
54. Schneider K, Loewendorf A, De Trez C, Fulton J, Rhode A, et al. (2008) Lymphotoxin-mediated crosstalk between B cells and splenic stroma promotes the initial type I interferon response to cytomegalovirus. Cell host & microbe 3: 67-76
55. Hsu KM, Pratt JR, Akers WJ, Achilefu SI, Yokoyama WM (2009) Murine cytomegalovirus displays selective infection of cells within hours after systemic administration. The Journal of general virology 90: 33-43
56. Barral P, Polzella P, Bruckbauer A, van Rooijen N, Besra GS, et al. (2010) CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nature immunology 11: 303-312
57. Cyster JG (2010) B cell follicles and antigen encounters of the third kind. Nature immunology 11: 989-996
58. Klaas M, Crocker PR (2012) Sialoadhesin in recognition of self and non-self. Seminars in immunopathology 34: 353-364
59. Phan TG, Grigorova I, Okada T, Cyster JG (2007) Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nature immunology 8: 992-1000
60. Moseman EA, Iannacone M, Bosurgi L, Tonti E, Chevrier N, et al. (2012) B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity. Immunity 36: 415-426
61. Honke N, Shaabani N, Cadeddu G, Sorg UR, Zhang DE, et al. (2012) Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nature immunology 13: 51-57
62. Iannacone M, Moseman EA, Tonti E, Bosurgi L, Junt T, et al. (2010) Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature 465: 1079-1083
63. Eloranta ML, Alm GV (1999) Splenic marginal metallophilic macrophages and marginal zone macrophages are the major interferon-alpha/beta producers in mice upon intravenous challenge with herpes simplex virus. Scandinavian journal of immunology 49: 391-394
64. Klaas M, Oetke C, Lewis LE, Erwig LP, Heikema AP, et al. (2012) Sialoadhesin promotes rapid proinflammatory and type I IFN responses to a sialylated pathogen, Campylobacter jejuni. Journal of immunology 189: 2414-2422
65. Kutsch S, Degrandi D, Pfeffer K (2008) Immediate lymphotoxin beta receptormediated transcriptional response in host defense against L. monocytogenes. Immunobiology 213: 353-366
66. Summers deLuca L, Ng D, Gao Y, Wortzman ME, Watts TH, et al. (2011) LTbetaR signaling in dendritic cells induces a type I IFN response that is required for optimal clonal expansion of CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America 108: 2046-2051.
67. Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, et al. (2011) Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. Journal of immunology 186: 5142-5150
68. Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, et al. (2012) IFNalpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119: 1407-1417
69. Heesters BA, Das A, Chatterjee P, Carroll MC (2014) Do follicular dendritic cells regulate lupus-specific B cells? Mol Immunol epub
70. Yao Y, Liu Z, Jallal B, Shen N, Ronnblom L (2013) Type I interferons in Sjogren's syndrome. Autoimmunity reviews 12: 558-566
71. Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ, et al. (2007) Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis and rheumatism 56: 1579-1588
72. Yoshida S, Arakawa F, Higuchi F, Ishibashi Y, Goto M, et al. (2012) Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection: up-regulation of inflammationassociated STAT1, IRF1, CXCL9, CXCL10, and CCL5. Scandinavian journal of rheumatology 41: 170-179
73. Elkon KB, Santer DM (2012) Complement, interferon and lupus. Curr Opin Immunol 24: 665-670
74. Migliorini A, Anders HJ (2012) A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nature reviews Nephrology 8: 183-189
75. Browning JL, Dougas I, Ngam-ek A, Bourdon PR, Ehrenfels BN, et al. (1995) Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. Journal of immunology 154: 33-46